ASD-CoV is a novel formulation of intestinally absorbed oral alpha-cyclodextrin as a unique 'intermittent fasting mimetic' (CoM pat. pend). ASD-CoV reduces the serum phospholipids needed during the life cycle of coronaviruses, incl. SARS-CoV-2, which causes COVID-19:
- virus entry (endocytosis)
- virus replication and transcription (DMV)
- virus assembly (Golgi complex)
ASD-CoV can be brought to marked within weeks under an NDIN and is safe enough to be taken before an infection has occured. A potential side effect is a slight reduction of body weight from the excretion of the lipids.
ASD-CoV also improves autophagy, a process that is involved in the etiology of many age-related diseases, including neurodegenerative diseases, such as Alzheimer's, Parkinson's, Huntington's, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), see the AGING tab.
See the PAPERS tab for publications and CoV-related media.